ClinicalTrials.gg
CompletedNCT07168902Updated Jul 22, 2026

Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension

A Phase 2 interventional study of BL1107 Low dose and BL1107 High dose in Glaucoma, sponsored by Bausch & Lomb Incorporated. Completed at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 490 studies in Glaucoma with a site in United States — 75 open to participants now, 94 under way, 5 of them phase 3. Glaucoma · United States.

Enrollment
62nd of 364
252 · median 79
Started
2025
with 28 others
Phase 2
66 of 490
4 open now
Registered
453rd of 490
by date

Among the 490 studies in Glaucoma with a site in United States, this one is the 62nd largest by enrollment of the 364 interventional ones that give a count, is one of 29 that started in 2025, is one of 66 in phase 2, and was the 453rd registered.

Glaucoma

1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.

Browse Glaucoma studies →

Open to participants now

75 of the 490 studies in Glaucoma with a site in United States are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 490 studies in Glaucoma with a site in United States, or all of them as a file.
02

Study summary

Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults with Primary Open Angle Glaucoma or Ocular Hypertension

Read the detailed description

This study will evaluate the safety and efficacy of BL1107 in adults with primary open-angle glaucoma or ocular hypertension in both eyes. This is a randomized, double-masked, parallel comparison to evaluate two concentrations of BL1107 in both eyes compared with timolol 0.5% for 28 days.

03

Conditions studied

  • Glaucoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ocular hypertension or primary open-angle glaucoma in each eye

Exclusion criteria

Exclusion criteria:

  • History of orthostatic hypotension
  • Any active ocular disease
  • Anticipated wearing of contact lenses during study
  • to pupil dilation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
252 participants (actual)

Study arms

  • Experimental
    BL1107 Low dose

    Drug: BL1107 Low dose

  • Experimental
    BL1107 High dose

    Drug: BL1107 High dose

  • Active comparator
    Timolol maleate 0.5%

    Drug: Timolol maleate 0.5%

Interventions

  • DrugBL1107 Low dose

    Dosed twice daily for 28 days.

  • DrugBL1107 High dose

    Dosed twice daily for 28 days.

  • DrugTimololStudies of TimololTimolol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Dosed twice daily for 28 days.

06

What researchers measure

Primary outcomes

  1. Change from baseline in visual field mean deviation in the study eye at Day 28/Exit.

    Time frame: Assessed at Day 28

Secondary outcomes

  1. Proportion of participants achieving ≥15-letter improvement in low-luminance best-corrected visual acuity (LL-BCVA) in the study eye at Day 28/Exit.

    Time frame: Assessed at Day 28

  2. Proportion of participants achieving ≥10-letter improvement in low-luminance best-corrected visual acuity (LL-BCVA) in the study eye at Day 28/Exit.

    Time frame: Assessed at Day 28

  3. Hour-matched change from Baseline in intraocular pressure (IOP) in the study eye at Day 28/Exit.

    Time frame: Assessed at Day 28

07

Study locations

14 sites
  • Global Research Management, Inc.
    Glendale, California 91204, United States
  • Eye Research Foundation
    Newport Beach, California 92663, United States
  • California Eye Specialist Medical Group, LLC
    Pasadena, California 91107, United States
  • Eye Associates of Fort Myers
    Fort Myers, Florida 33901, United States
  • Levenson Eye Associates
    Jacksonville, Florida 32204, United States
  • Central Florida Eye Associates
    Lakeland, Florida 33805, United States
  • Lee Shettle Eye and Hearing
    Largo, Florida 33773, United States
  • Clayton Eye Clinical Research, LLC
    Morrow, Georgia 30260, United States
  • Coastal Research Associates, LLC
    Roswell, Georgia 30076, United States
  • Heart of America Eye Care
    Shawnee Mission, Kansas 66204, United States
  • Andover Eye Associates
    Andover, Massachusetts 01810, United States
  • Scott & Christie and Associates, PC
    Cranberry Township, Pennsylvania 16066, United States
  • Total Eye Care, P.A.
    Memphis, Tennessee 38119, United States
  • Houston Eye Associates
    Houston, Texas 77025, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in May 2026, 6 months.

Of 23 industry-sponsored phase 2 interventional studies under Glaucoma, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 11. This study's 6 months is below that.

Counting every sponsor, half of 32 studies reached it within 11 months; a quarter within 6 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2025
First posted
Sep 11, 2025
StartActual
Oct 24, 2025
Primary completionActual
May 18, 2026
CompletionActual
May 18, 2026
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07168902
Responsible party
Sponsor
First posted
Sep 11, 2025
Start date
Oct 24, 2025
Primary completion
May 18, 2026
Completion
May 18, 2026
Last update
Jul 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion